Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Intangibles (2016 - 2025)

Historic Intangibles for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $5.5 million.

  • RedHill Biopharma's Intangibles fell 55.74% to $5.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.5 million, marking a year-over-year decrease of 55.74%. This contributed to the annual value of $5.5 million for FY2024, which is 55.58% down from last year.
  • Latest data reveals that RedHill Biopharma reported Intangibles of $5.5 million as of Q2 2025, which was down 55.74% from $5.5 million recorded in Q4 2024.
  • Over the past 5 years, RedHill Biopharma's Intangibles peaked at $89.4 million during Q4 2021, and registered a low of $5.5 million during Q2 2025.
  • Over the past 5 years, RedHill Biopharma's median Intangibles value was $67.9 million (recorded in 2022), while the average stood at $47.9 million.
  • Its Intangibles has fluctuated over the past 5 years, first skyrocketed by 44288.06% in 2021, then plummeted by 9375.87% in 2023.
  • Over the past 5 years, RedHill Biopharma's Intangibles (Quarter) stood at $89.4 million in 2021, then changed by 0.0% to $89.4 million in 2022, then tumbled by 93.76% to $5.6 million in 2023, then dropped by 0.56% to $5.5 million in 2024, then dropped by 0.29% to $5.5 million in 2025.
  • Its Intangibles stands at $5.5 million for Q2 2025, versus $5.5 million for Q4 2024 and $5.6 million for Q2 2024.